Literature DB >> 15610528

Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.

Jordi Graells1, Antonia Vinyals, Agnes Figueras, Ana Llorens, Abelardo Moreno, Joaquim Marcoval, F Jesus Gonzalez, Angels Fabra.   

Abstract

Vascular endothelial growth factor (VEGF) is an important mediator of tumor-associated angiogenesis, and consequently it has been associated with metastasis. We report here that the overexpression of VEGF(165) in melanoma xenografts promotes an acceleration of tumor growth and an increase in angiogenesis as well as the spontaneous metastasis formation. In addition, VEGF receptors (VEGFR)1, VEGFR2 and neurophilin-1 are expressed in A375 melanoma cells. Forced overexpression of VEGF in these cells induces cell growth and triggers survival activity in serum-starved cultures, by a mechanism dependent on the mitogen-activating protein kinase signaling pathway. Furthermore, these effects are dependent MEK 1/2 activity. Kinase domain region-specific tyrosine kinase inhibitors dramatically reduced DNA synthesis to 20% with respect to the controls, although they did not completely suppress either the p44 or p42-phosphorylated forms of extracellular signal-regulated protein kinase. These inhibitors also provoked a decrease in Akt phosphorylation. We observed a dramatic reduction in survival after treatment with phosphatidylinositol 3'-kinase (PI3K)-specific inhibitor in the presence of specific tyrosinase inhibitors. We suggest that the overproduction of VEGF(165) concomitantly expressed with its receptors favors cell growth and survival of melanoma cells through MAPK and PI3K signaling pathways. These data support the involvement in melanoma growth and survival of a VEGF-dependent internal autocrine loop mechanism, at least in vitro.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15610528     DOI: 10.1111/j.0022-202X.2004.23460.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  40 in total

Review 1.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

2.  Targeting angiogenesis in melanoma: prospects for the future.

Authors:  P G Corrie; B Basu; K Ahmad Zaki
Journal:  Ther Adv Med Oncol       Date:  2010-11       Impact factor: 8.168

3.  Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.

Authors:  Toshinori Hinoue; Daniel J Weisenberger; Fei Pan; Mihaela Campan; Myungjin Kim; Joanne Young; Vicki L Whitehall; Barbara A Leggett; Peter W Laird
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

Review 4.  Therapy for metastatic melanoma: the past, present, and future.

Authors:  Laura Finn; Svetomir N Markovic; Richard W Joseph
Journal:  BMC Med       Date:  2012-03-02       Impact factor: 8.775

5.  Gene expression profile of B 16(F10) murine melanoma cells exposed to hypoxic conditions in vitro.

Authors:  Magdalena Olbryt; Michał Jarzab; Joanna Jazowiecka-Rakus; Krzysztof Simek; Stanisław Szala; Aleksander Sochanik
Journal:  Gene Expr       Date:  2006

6.  Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Authors:  Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

7.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.

Authors:  Una Adamcic; Karolina Skowronski; Craig Peters; Jodi Morrison; Brenda L Coomber
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

8.  Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Authors:  Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  Targeted therapy in melanoma.

Authors:  Hussein Tawbi; Neelima Nimmagadda
Journal:  Biologics       Date:  2009-12-29

10.  EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.

Authors:  Faten Bougatef; Suzanne Menashi; Farah Khayati; Benyoussef Naïmi; Raphaël Porcher; Marie-Pierre Podgorniak; Guy Millot; Anne Janin; Fabien Calvo; Céleste Lebbé; Samia Mourah
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.